Pre-B-cell development in the absence of λ5 in transgenic mice expressing a heavy-chain disease protein  by Corcos, Daniel et al.
Pre-B-cell development in the absence of X5 in transgenic
mice expressing a heavy-chain disease protein
Daniel Corcos*, Olga Dunda*, Cecile Butort, Jean-Yves Cesbront,
Patrick Lores*, Danielle Bucchini* and Jacques Jami*
*lInstitut Cochin de Genetique Moleculaire, Unite INSERM 257, 24 rue du Faubourg St-Jacques, 75014 Paris, France.
t Unit6 INSERM 152, 27 rue du Faubourg St-Jacques, 75014 Paris, France. *lnstitut Pasteur, Unit6 Mixte INSERM U 415,
1 rue du Professeur Calmette, 59019 Lille, France
Background: Heavy-chain diseases (HCDs) are human
lymphoproliferative neoplasias that are characterized by
the secretion of truncated immunoglobulin heavy chains
devoid of light chains. We have previously proposed -
by analogy to the process by which mutated growth
factor receptors can be oncogenic - that because the
genetic defects in HCDs result in the production of
abnormal membrane-associated heavy chains lacking an
antigen-binding domain, these abnormal B-cell antigen
receptors might engage in ligand-independent signalling.
Normal pre-B-cell development requires the presence of
the pre-B-cell receptor, formed by the association of .
heavy chains with two polypeptides - so-called surrogate
light chains, Vpre B and X5 - that are homologous to the
variable and constant portions of immunoglobulin light
chains, respectively. To assess whether amino-terminal
truncation of membrane-associated heavy chains results in
their constitutive activation, we have examined the ability
of a HCD-associated Ip protein to promote pre-B-cell
development in transgenic mice.
Results: When the p. HCD transgene is introduced into
SCID mice, CD43- pre-B cells develop normally. To
determine whether this pre-B-cell development requires
surrogate light chains, we backcrossed mice expressing
full-length or truncated p. transgenes with 5-deficient
mice. Our results show that the truncated heavy chain,
but not the normal chain, is able to promote pre-B-cell
development in the absence of X5. We also show that
truncated p. chains spontaneously aggregate at the surface
of bone marrow cells.
Conclusions: Expression of the truncated I heavy chain
overrides a tightly controlled step of pre-B-cell devel-
opment, which strongly suggests that a constitutive signal
is delivered by the truncated p. chain disease protein. The
self-aggregation of chain disease proteins might
account for this constitutive activation. We conclude that
amino-terminal truncation of heavy chains could play a
role in the genesis of HCD neoplasia if it occurs at an
appropriate stage of B-cell differentiation, namely in a
mature B cell.
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Background
Heavy-chain diseases (HCDs) are a set of human
lymphoproliferative disorders [1] that are characterized
by the clonal expansion of cells secreting truncated
immunoglobulin heavy chains without associated light
chains (and thus without the antigen-binding domain);
such HCD proteins are encoded by abnormal heavy-
chain genes [2]. We have previously hypothesized that
the clonal expansion and differentiation of neoplastic
HCD cells to the plasma-cell stage are related to a ligand-
independent activation of signalling by the membrane-
associated form of the truncated heavy chain [3], a
situation that is analogous to the constitutive activation of
truncated oncogenic growth factor receptors [4].
According to this model, the truncated antigen receptor
has a constitutive activity which mimics antigen binding,
favouring the proliferation of mature B-cells and their
differentiation to the plasma-cell stage.
In order to study the activity of a membrane-associated
HCD protein, we created several lines of transgenic mice
expressing a truncated human p. heavy chain (AVVL).
The transgene, which lacks the rearranged VDJ exon,
encodes a molecule similar to that found in two patients
with HCD [5]. As a consequence of the early expres-
sion of the membrane-bound AVIt protein, rearrange-
ment to V and DJ immunoglobulin gene segments is
inhibited, and the transgene-encoded truncated pI mol-
ecule is expressed without surrogate light chain on the
surface of cells that reach the peripheral lymphoid sys-
tem [5]. This was an intriguing finding, because nor-
mally pre-B-cell development requires the presence of
the pre-B-cell receptor, which is formed by the associa-
tion of I heavy chains with two invariant polypeptides,
VpreB and X5, which are homologous to the variable
and constant portions of immunoglobulin light chains,
respectively [6]. This complex, which might also contain
the Ig-ot and Ig-13 co-receptor molecules [7,8], is
involved in the transition of precursor B220+ cells from
the CD43 + to the CD43- stage (Fig.1; [9]). The AVp.
molecule contains the heavy-chain constant domains
necessary for its association with Ig-t and Ig-P [10,11],
but AVp. does not bind to light chains. This suggests that
the truncated p. protein is also unable to bind to V re B
and X5, implying that pre-B-cell development in Vp.
mice is dependent on a pre-B-cell receptor devoid of
these molecules.
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Fig. 1. The role of I. heavy-chain-bearing receptors in normal B-cell development. Well characterized developmental steps involving
the complete RI heavy chain (after productive VDJ recombination) are shown schematically (from [6,17,18,26,28,38-40]). Other possi-
ble roles of the complete Cp chain (which is shown in pink) are not excluded. Surrogate light chains X5 and VpreB are shown in yellow.
It should be noted that surface expression of the normal pre-B-cell receptor is low [39] or undetectable [401.
In AVi-transgenic mice, there is a variable level of
B-cell depletion in peripheral lymphoid organs [5], but it
is not clear at which developmental stage this depletion
occurs. In this study, we wanted to determine whether
the truncated immunoglobulin heavy chain is able to
promote maturation and/or survival of pre-B cells and, if
this was the case, whether association with surrogate light
chains (X5/VpreB) is required. We show here that amino-
terminal truncation of the Ip chain results in pre-B-cell
development which is independent of X5. We further
suggest a mechanism for constitutive activation of the
truncated p, chain, involving both self-aggregation of
truncated chains and their failure to associate with the
BiP chaperone.
Results
Expression of the AV~I protein permits the generation of
pre-B cells
Defining the developmental stages of B cells in AVt-
transgenic mice is complicated by the fact that the trun-
cated heavy chain can be expressed at high levels on the
cell surface in the absence of light-chain production [5],
presumably because the mutant chain does not bind sta-
bly to the heavy-chain-binding protein BiP [12]. As a
consequence, late pre-B cells cannot be distinguished
from immature B cells by cell-surface markers. In order
to characterize the effect of the truncated heavy chain on
pre-B-cell development, therefore, we introduced a trans-
gene encoding either AVI or a complete I. chain into
mice homozygous for the scid mutation [13]. In these
mice, which are unable to make productive rearrange-
ments of their immunoglobulin genes, lymphopoiesis
aborts after the pro-B CD43+ cell stage (Fig. 2a) [14].
The ability of the AVI transgene to promote pre-B-cell
development in mice was compared to that of a complete
jp transgene, termed hSp6, which consisted of the
human constant p, region and a rearranged mouse heavy-
chain variable (VH) region corresponding to the Sp6
idiotype [15]. In the hSp6-39 mouse line, which we
used, the transgene - the expression of which was
detected using anti-human IgM antibodies - was
expressed on the surface of most B cells (Table 1).
Expression of the chimeric heavy chain resulted in allelic
exclusion of endogenous heavy chains.
Transgenic mice expressing either AVpI or hSp6 were
serially crossed with homozygous SCID mice for two or
more generations. Homozygosity for the scid mutation
was diagnosed on the basis of serum immunoglobulin lev-
els, because AVp.- and h[LSp6-transgenic non-SCID mice
have nearly normal levels of endogenous immunoglobulin
by four weeks (produced by plasma cells that have escaped
allelic exclusion). Mice lacking detectable levels of
immunoglobulin were considered homozygous for the sid
mutation. Introduction of the complete px transgene pro-
moted development of CD43- pre-B cells in these mice
(Fig. 2a) but did not promote B-cell development, as pre-
viously shown by Reichman-Fried et al. [16]. The AVpL
transgene was as efficient as the complete transgene in
generating B220+ CD43- cells (Fig. 2a) in bone marrow,
and, like the complete Ip gene, it did not lead to a substan-
tial increase of lymphoid cell numbers in the spleen (data
not shown). This latter result might be due to cell lethality
caused by chromosomal breaks, formed as a result of faulty
light-chain gene rearrangements in SCID mice [16].
A high proportion of bone marrow cells from
AVL SCID mice expressed high levels of cell-surface
AVp, protein (Fig. 2b). The absence of light-chain gene
rearrangements in bone marrow and spleen DNA from
both types of transgenic SCID animals was confirmed by
polymerase chain reaction (PCR) analysis (Fig. 3). By
these two criteria - presence of the cells mainly in the
bone marrow, and absence of light-chain gene rearrange-
ment - we infer that B220+ CD43- cells from
AVp. SCID mice are pre-B cells, although a number of
them express the truncated immunoglobulin on their
surface. Because the AVpI transgene has the same ability
as the complete px transgene to promote the development
of B220+ CD43- cells, we conclude that the truncated
molecule, like the normal one, can participate in the
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Fig. 2. Flow cytometric analysis of bone marrow cells from
BALB/c, SCID, AViL SCID or hSp6 SCID mice. Cells were
stained with anti-CD43 and either (a) anti-B220 antibodies or (b)
anti-human IgM antibodies. (a) In BALB/c control mice, the
upper left quadrant represents B cells and CD43- pre-B cells,
whereas in transgenic SCID mice, it represents pre-B cells only.
B220+ CD43 + cells (upper right quadrant) are here termed pro-B
cells. (b) The AVi. molecule was detected on the surface of SCID
transgenic cells using anti-human IgM antibodies, whereas the
complete chain was not seen (even though it was easily
detected on the surface of B cells of hptSp6 wild-type mice; data
not shown). The age of the mice ranged from three to five
months. Double staining using anti-human IgM and anti-B220
antibodies indicated that the majority of cells expressing AVp.
were B220 + (data not shown). Analyses were carried out on cells
in the lymphocyte gate defined by forward and side scatter. Con-
tour plots representative from three experiments are shown. Both
axes correspond to log1O fluorescence. Numbers indicate the
percentage of gated cells in each quadrant or region.
formation of a pre-B-cell receptor that is able to trans-
duce signals to the inside of the cell.
The AV. protein supports the generation of CD43- pre-B
cells in the absence of X5 protein
To examine the possibility that AVp, acts in the absence
of X5, we backcrossed mice containing the AVp. and
complete p. transgenes with X5T/X5T mice [17]. These
mice, which are deficient in the X5 protein as a result of a
targeted disruption of the X5 gene, exhibit a marked
reduction in the number of CD43- pre-B cells and
immature B cells [9,18], which together constitute the
large majority of B220+ CD43- cells in normal bone
marrow. We thus examined the effect of the two different
p, transgenes, introduced by serial crossings into X5-
deficient mice, on this bone marrow cell population.
The analyses shown in Figure 4 indicate that the com-
plete I, transgene had no effect, whereas the AVI gene
was able to support the generation of the B220+ CD43-
population. As in mice that have the wild-type X5 gene,
most CD43- cells were small and expressed cell-surface
AVI, proteins but not the endogenous heavy chain (data
not shown). The mice used for the analysis shown in
Figure 4 were two to three months old. The same results
were obtained using six- to eight-month-old transgenic
X5-deficient mice. The absolute numbers of bone mar-
row B2201ow CD43- cells - pre-B cells and immature B
cells, equivalent to fractions D + E as defined by Hardy et
al. [19] - were less than 1 x 105 per femur in all of the
X5-deficient mice and in all of the X5-deficient mice car-
rying the complete p, transgene that were analyzed, in
agreement with a published report [9]. In the three X5-
deficient mice carrying the AVp. transgene, these num-
bers ranged from 3.5 x 105 to 12 x 105 cells per femur,
and a similar number of these cells were found in AVpz
mice carrying the wild-type .5 gene. As in mice carry-
ing the wild-type X5 gene, B cells expressing cell-surface
AVI. protein, but not expressing endogenous p, chains,
were found in the spleen (data not shown). We thus con-
clude that pre-B-cell development in AVIL-transgenic
mice does not require X5.
Pre-B-cell development in various AVti-transgenic lines
It has recently been shown that, in a unique y2b trans-
genic mouse line, B-cell development is dependent on
the transgene integration site [20]. We therefore wanted
to determine whether the ability to promote pre-B-cell
development was a feature unique to our AV[.-6 line. In
all AVu. and AVI.m lines (the AVtm construct differs
from AVp. in that it encodes only the membrane-bound
form of the truncated human p. heavy chain), high-level
expression of the truncated p. human molecule on the
cell surface is always associated with allelic exclusion of
endogenous IgM expression ([5] and data not shown). In
four AVt. lines and one AVI.m line, very few B cells
expressed endogenous cell-surface IgM (Table 1), indi-
cating that pre-B-cell development is dependent on the
transgenic molecule. We therefore studied B-lineage cells
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In all but one mouse, the numbers of B2201°W CD43-
cells were comparable to those in transgenic mice
expressing the complete pi chain (Table 1). Therefore,
the AV[, protein is able to sustain pre-B-cell develop-
ment irrespective of the transgene integration site. In
addition, transgenic AVp. and AVpm lines differ from
hiLSp6-transgenic mice or control mice in that they lack
mature B cells (B220high cells in Table 1 and Fig. 5).
AVp. chains form patches on the cell surface
Because our results suggested that the AV[l molecule is
able to mediate intracellular signal transduction in the
absence of the putative ligand for the pre-B-cell
receptor, we investigated the mechanism responsible for
this constitutive activation. The most likely hypothesis
was that this signalling might involve the spontaneous
aggregation of truncated membrane-associated heavy
chains on the cell surface. This hypothesis is strength-
ened by the fact that serum HCD proteins have a ten-
dency to polymerize [1]. We therefore determined
whether surface AVp. molecules have a tendency to
aggregate spontaneously. Bone marrow and spleen cells
from AVer- and hp.Sp6-transgenic mice were collected at
4 C in the presence of sodium azide, and incubated
under identical conditions with a biotinylated anti-
human IgM antibodies, followed by staining with
streptavidin-conjugated phycoerythrin.
In cells from hlpSp6-transgenic mice, the staining of cell-
surface immunoglobulin was in a punctate pattern
(Figs 6e,g), whereas cells from non-transgenic mice were
not stained (Figs 6a,c). By contrast, staining was
reproducibly patchy in cells from either AVpL-transgenic
mice, or AVpL-transgenic X5-deficient mice (data not
Fig. 3. PCR analysis of K gene rearrangements in (a) bone marrow and (b) spleen from BALB/c, hSp6, AV.l, SCID, hLSp6 SCID or
AVi. SCID mice. (c) Serial four-fold dilution of spleen DNA from normal mice in tail DNA. Upper panels show the 0.5 kbp amplifica-
tion products, corresponding to VKJK1 joints. In all assays, the non-allelic insulin (INS) genes were co-amplified (lower panels), giving
rise to two bands at 0.23 kbp and 0.72 kbp, which corresponded to amplification products of insulin genes 1 and 2, respectively, and
to an additional band which was intermediate in size. Total bone marrow and total spleen cells were used in these experiments. The
non-SCID AVIL-transgenic mouse had a three-fold reduction in the percentage of spleen B220+ cells compared to control mice. Quan-
tification of rearrangements, performed using a Phosphorimager (Molecular Dynamics), indicated that there was no difference between
the levels of K rearrangements per B220 + cell in non-SCID AV.-transgenic mice and control mice.
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shown). A striking example is shown in Figure 6g, and a
more representative example in Figure 6k. The punctate
pattern seen in hLSp6 cells is typical of microvillous
(a) k5T/+ k5T/;5T
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Fig. 4. Flow cytometric analysis of bone marrow from (a) hplSp6-
or (b) AVpL-transgenic mice heterozygous or homozygous for a
targeted mutation at the x5 locus (5T). Bone marrow cells from
two- to three-month-old animals were analyzed after two-color
staining for CD43 and B220, which was performed as outlined in
Fig. 2. (a) The complete p. chain does not increase the percentage
of B220 + CD43- cells in 5-deficient mice. (b) B220 + CD43-
cells are produced in AVIS mice lacking X5. Note the lack of
mature B cells (B220 high) due to the AVi. transgene. The mice
used in (b) were all littermates, whereas in (a) an age-matched
X5T/X5T non-transgenic mouse was used. Numbers indicate the
percentage of gated cells in each quadrant.
staining, indicating a uniform surface distribution of the
heavy chain over the microvilli of the cell surface,
whereas the patchy pattern displayed by AVI cells is
consistent with aggregation of the heavy chains. An alter-
-A v S . __ - . .' . _ A._ A I 
natve explanation is tnat tme patcny pattern is annooay-
induced, but this should only occur to a very limited
extent as our observations were carried out within
10 minutes after transfer to room temperature. We can-
not, of course, rule out the possibility that AVV. chains
are present in aggregates of a size too small to be identifi-
able by light microscopy, and that the addition of anti-
bodies induces very rapid patching due to the high
multivalency of the aggregated AVpI chains. We did
observe antibody-induced patching after prolonged incu-
bation of hp.Sp6 cells at room temperature, but its extent
never reached that observed with AVii-transgenic cells.
The difference in labelling patterns was consistent over a
large number of cells, and was reproducible from experi-
ment to experiment. We therefore conclude that IgM
containing the hp.Sp6 chain behaves like normal mouse
IgM, whereas AVI. chains spontaneously aggregate.
Discussion
Signalling by the pre-B-cell receptor is generally thought
to involve an interaction between an unknown ligand and
the variable region of the p. heavy chain or X5/VpreB [6].
The ability of the AVp. molecule to support the genera-
tion of CD43- pre-B cells in the absence of X5 (or con-
ventional light chains) can therefore be taken as strong
evidence for ligand-independent (constitutive) signalling.
Alternatively, the putative ligand could interact with the
constant region of the pL heavy chain. This possibility
seems very unlikely, because transgenic mice expressing 8,
a and y2b chains are able to sustain normal B-cell devel-
opment [20-23] even though their constant regions differ
notably from that of p.. It has also recently been suggested
that 5 might not act as part of a receptor, but as an
adhesion molecule [24]. This now appears unlikely, given
the ability of the AVp. molecule to compensate for a lack
of X5. Finally, another model suggests that the normal
pre-B-cell complex displays constitutive activity [25]. If
true, this model would also imply there is ligand-inde-
pendent signalling by the truncated complex.
A major prediction of our initial hypothesis of HCD
pathogenesis is that expression of the membrane-associated
form of an HCD protein would confer constitutive activa-
tion on the B-cell receptor. In the neoplastic cells of HCD
patients, signalling by the abnormal B-cell receptor would
mimic antigen-induced signalling on mature B cells,
favouring selective clonal expansion of cells with abnormal
receptors in the absence of antigen. Tumorigenesis does
not occur in AVpI-transgenic mice, and expression of the
transgene prevents full B-cell development (D.C., unpub-
lished observations, and Fig. 7). This may be explained by
the fact that the transgene is expressed early in B-cell
development, as evidenced by allelic exclusion of endoge-
nous heavy-chain genes [5]. Stimulation of the antigen
0
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Fig. 5. Flow cytometric analysis of bone marrow from BALB/c, hSp6-39 and AVe-6 mice after two-color staining for B220 and human
IgM. Analyses were carried out on cells in the lymphocyte gate defined by forward and side scatter. Data are shown as dot plots. Num-
bers indicate the percentage of gated cells in each quadrant. In BALB/c mice, cells can be classified as B220-, B2201°w and B220high
cells. These cells are not recognized by the anti-human IgM antibody. In hl~Sp6 mice, human IgM is expressed by mature (B220high)
and immature (B22 01°w ) B cells. In contrast to hSp6 mice, AV-transgenic mice exhibit a marked reduction in the percentage of
mature B cells. B22010w, higM-positive cells comprise both immature B cells (as in hSp6 mice) and pre-B cells expressing the trun-
cated IgM on their surface (as in AVR-transgenic SCID mice). In addition, some B220v erY low cells (6 % of the gated cells) express the
transgene on the cell surface. These cells may be pro-B cells or, alternatively, immature B cells that have downregulated B220, similar
to those found in the spleen [5]. These cells are not scored as B220 + in Table 1.
receptor of immature B cells has been shown, in numerous
cases, to induce tolerance and to inhibit the development
of mature B cells [26-28] (see Fig. 1). The phenotype of
the AVp.-transgenic cells found in the peripheral lym-
phoid system is consistent with persistent signalling at the
immature B-cell stage (A. Grandien and D.C., unpub-
lished observations). However, such evidence is indirect,
and the best proof for constitutive activation rests on the
effects of HCD proteins at the pre-B-cell stage.
The mechanism by which amino-terminal truncation of
membrane-associated heavy chains leads to ligand-
independent signalling is likely to involve spontaneous
aggregation. Interestingly, isolated normal heavy chains
also tend to aggregate, and they are only solubilized by
light chains [29]. However, in normal cells, heavy chains
- in the absence of light chains - interact with BiPs,
which retain them in the lumen of the endoplasmic
reticulum. Unlike normal p, chains, transgenic . chain
disease proteins are exported to the cell surface in the
absence of light chains, indicating that they do not stably
interact with BiP (Fig. 2b). Moreover, it has been shown
by others that naturally occurring truncated AVp chains
do not associate with BiP [12]. Therefore, we suggest
that the lack of interaction between these proteins may
play a role in the self aggregation of AVp,. BiP is a
Fig. 6. Detection of human heavy chains
on the surface of spleen and bone mar-
row cells of wild-type (BALB/c) and
transgenic mice by immunofluores-
cence. Magnification: x 750.
hlgM hIgM hIgM
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Fig. 7. B-cell development in AV[l-transgenic mice (bottom), in comparison with normal B-cell development (top). In the case of AVp.-
transgenic mice, the truncated . chain appears on the cell surface at high levels in the absence of light chain. Expression of the AVR.
protein precludes the development of mature (CD23+ B220high) B cells (Table 1 and data not shown). Green circles represent the
heavy-chain binding protein BiP, which interacts with the normal chain.
member of the hsp70 family of proteins, among the
functions of which is to assist protein folding and to pre-
vent aggregation [30]. Thus, it is tempting to speculate
that membrane-associated HCD proteins might not be
subject to regulation by BiP.
Conclusions
Expression of the truncated p. heavy chain promotes pre-
B-cell development in the absence of surrogate light
chains. This result strongly suggests that amino-terminal
truncation of Ix is responsible for constitutive activation
of its signalling capacity. In theory, constant stimulation
of a mature B cell through its antigen receptor could pro-
vide a selective advantage to the cell, by promoting pro-
liferation or survival, which would favour the emergence
of a neoplasia [3,31]. This seems to imply that, in HCD,
the genetic event leading to abnormal immunoglobulin
production occurs after the negative-selection stage, in
mature B cells (see Fig. 7). In support of this idea, it
has been suggested that some HCD proteins might be
generated during the course of the constant region
switch [32,33]. However, it is not clear whether the pro-
duction of truncated membrane-associated heavy chains,
although necessary, would be sufficient to produce the
disease, as carcinogenesis usually requires several genetic
events [34]. In addition, in the case of (x chain disease,
environmental factors might be required in order to sus-
tain the abnormal proliferation [1]. An interesting possi-
bility for membrane-associated heavy chains is that the
mechanism by which they are constitutively activated
might be related to their lack of regulation by the BiP
chaperone. Because BiP is ubiquitous and is able to bind
to numerous polypeptides, we believe that similar
mechanisms may be involved in the activation of amino-
terminally truncated growth factor receptors.
Materials and methods
Construction of the hp.sp6 plasmid
The 9 kbp Hpal fragment of the AV[L plasmid [5], which
encompasses all of the constant region exons, was inserted
into the pSV36 plasmid, which had been digested with EcoRI
and blunt-ended. The pSV36 plasmid (provided by A. Iglesias
[21]) was designed to allow the insertion of DNA at a unique
EcoRI site downstream of the mouse VH Sp6 region. All
manipulations were carried out using standard procedures [35].
Transgenic mouse lines
Mice expressing the AVp. and AVlm transgenes have been
described [5]; hSp6-transgenic mice were obtained as
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previously reported [5]. The hSp6 plasmid was linearized
with BamHI prior to injection. Mice expressing the hSp6
transgene were identified by dot-blot hybridization of tail
DNA using the pSV2-gpt plasmid. Transgenic mouse lines
were maintained through matings with BALB/c mice; k5-defi-
cient mice [17], obtained from W. Muller and K. Rajewsky,
were genotyped after breeding by PCR analysis of tail DNA.
These mice were kept in a conventional mouse breeding facil-
ity. C.B-17-SCID mice (provided by M. Lieberman) were
maintained in pathogen-free conditions. Diagnosis of homozy-
gosity for the scid mutation was performed using a competitive
radioimmunoassay for serum K chains.
Flow cytometric analysis
Spleen and bone marrow cells were stained with conjugated
antibodies and analyzed on a Coulter Elite Flow fluoro-
cytometer (Coulter Electronics, Hialeah, Florida). The follow-
ing antibodies were used: fluorescein-conjugated monoclonal
antihuman p, (Nordic, Tilburg, The Netherlands) or biotin-
conjugated monoclonal anti-human p (Janssen Chimica, Geel,
Belgium), fluorescein- or biotin-conjugated rat monoclonal
anti-mouse B220 (CALTAG Labs, San Fransisco, California),
fluoresceinated human-absorbed goat anti-mouse p (CALTAG
Labs) and fluoresceinated monoclonal anti-mouse CD43
(PharMingen, San Diego, California). Biotinylated antibodies
were detected by subsequent staining with phycoerythrin-con-
jugated streptavidin (CALTAG Labs). Dead cells were
excluded by propidium iodide staining. Analyses were carried
out on cells in the lymphocyte gate, defined by forward and
side scatter.
PCR analysis
Amplifications were performed on a DNA Thermal Cycler
(Perkin Elmer, Northwalk, Connecticut) using AmpliTaq
DNA Polymerase (Perkin Elmer). For the quantification of K
gene rearrangements, amplifications were performed as
described [36] using 30 ng of DNA (5 000 unsorted cells). In
all assays the nonallelic insulin (INS) genes were co-amplified
[5]. INS PCR products were detected using the labeled
oligonucleotide 5'-TGGGTGTGTAGAAGAAGCC-3'. One
fifth of each sample was subjected to agarose gel electrophoresis
and INS PCR products were visualized by ethidium bromide
staining; the sample volumes loaded for Southern blot
hybridization were then corrected to give similar amounts of
INS PCR products. The assay allows detection of less than %
normal B cells in a heterogeneous cell population. Mice defi-
cient in 5 were genotyped by PCR analysis of tail DNA,
using a primer located in the first exon of the 5 gene, 5' to
the neo gene in the 5T mutant - 5'-AGCTCAGAGTA-
GGACAGACT-3' -and a primer in the first intron, 3' to the
neo gene - 5'-GGCCTTGCAATTGATCGAGG-3', based
on the published sequence [37]. Amplification products of
0.37 kbp (wild-type allele) and 1.4 kbp (targeted) were
visualized by ethidium bromide staining.
Fluorescence microscopy
Spleen and bone marrow cells were stained at 4 C in PBS
containing 3 % BSA, 0.02 % sodium azide and biotin-conju-
gated monoclonal anti-human (mouse IgG1, MH15-1;
Janssen Chimica), followed by staining with phycoerythrin-
conjugated streptavidin (CALTAG Labs), as in the FACS analy-
sis. Cell pellets were resuspended in cold PBS. For observation,
5 1I cell suspension was placed between a glass slide and a cov-
erslip. Micrographs were obtained using a Nikon Microphot-
FXA, with an XF39 filter (excitation filter 550 + 30 nm,
dichroic mirror 575 nm, emission filter 615 ± 45 nm).
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